Tag Archives: Rintatolimod

Endocrine immune regulation in… women with CFS

Leveraging prior knowledge of endocrine immune regulation in the therapeutically relevant phenotyping of women with Chronic Fatigue Syndrome, by Matthew C Morris, Katherine Cooney, Hooman Sedghamiz, Maria Abreu, Fanny Collado, Elizabeth G Balbin, Travis JA Craddock, Nancy G Klimas, Gordon … Continue reading

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Endocrine immune regulation in… women with CFS

Making the Case For Ampligen and ME/CFS

Simmaron research blog post, by Cort Johnson 23 June 2016: Making the Case for Ampligen in Chronic Fatigue Syndrome (ME/CFS) Extracts: Ampligen has been in the FDA pipeline for so many years that it almost seems like a mirage at … Continue reading

Posted in News | Tagged , , , , | Comments Off on Making the Case For Ampligen and ME/CFS

Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)

Research abstract: Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating disease of unknown pathogenesis consisting of  a variety of flu-like symptoms including severe fatigue. Initial analysis of the use of rintatolimod (Poly I: Poly C12U), a selective TLR3 agonist, … Continue reading

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)